VHVolker Heinemann

Volker Heinemann

*This is an algorithmically generated author record based on publicly available information.

Volker Heinemann has a total of 84 co-authors. Here are the top co-authors by number of shared publications:

  • A. Schalhorn

    Klin Grosshadern, Medcl Clinic III, Munich, Germany; Klin St. Marien, Amberg, Germany; Klin gGmbH, Chemnitz, Germany; Oncological Practice, Ingolstadt, Germany; Klin, Augsburg, Germany; Klin, Garmisch-Partenkirchen, Germany; Klin Nord, Nuernberg, Germany; Krankenhaus, Zittau, Germany; Oncological Practice, Wuerzburg, Germany; Oncological Practice, Chemnitz, Germany

    3 shared publications
  • K. Possinger

    Central European Cooperative Oncology Group (CECOG) § , Schwarzspanierstrasse 7/5, A-1090 Vienna, Austria

    3 shared publications
  • W. Hiddemann

    Medizinische Klinik und Poliklinik III, CCC - Comprehensive Cancer Center, Klinikum der Ludwig-Maximilians-Universität München, Standort Großhadern

    3 shared publications
  • Gerhard Behre

    University Hospital Halle (Saale)

    2 shared publications
  • H. Wilke

    'fClinikum Grosshadern Munchen

    2 shared publications
  • M. Clemens

    2 shared publications

Latest Publications

  • Das metastasierte kolorektale Karzinom – Eine Analyse der Behandlungsmodalitäten und Überlebenszeiten gestern und heute

    by M. Michl, B. Holtzem, J. Koch, N. Moosmann, J. Holch, W. Hiddemann, V. Heinemann

    Hintergrund und Fragestellung: Die Behandlungsstrategien des metastasierten kolorektalen Karzinoms (mKRK) haben sich in den letzten Jahrzehnten stark verbessert, was sich in einer deutlichen Zunahme des Gesamtüberlebens (OS) ausdrückt. Die vorliegende Arbeit zeigt dies anhand des Vergleichs von zwei Patientenkollektiven. Patienten und Methoden: Im Rahmen von zwei aufeinanderfolgenden retrospektiven monozentrischen Analysen wurden zwei Patientenkollektive mit mKRK, die von 07/1994 bis 10/2007 (Zeitraum 1) bzw. von 11/2007 bis 05/2010 (Zeitraum 2) in unserem onkologischen Zentrum behandelt wurden, hinsichtlich der Patienten- und Tumorcharakteristika, verabreichter Therapieregime, erreichter Best Response unter Erstlinientherapie und dem Überleben verglichen. Das Überleben wurde nach Kaplan-Meier berechnet und graphisch dargestellt. Ergebnisse: Beide Patientenkollektive waren hinsichtlich des medianen Alters (63 bzw. 64 Jahre), Lokalisation des Primarius (Kolon 60 %, Rektum 40 %) sowie Anzahl und Lokalisation der Fernmetastasen (1 Organ ca. 75 %, ≥ 2 Organe ca. 25 %, nur Leber 55 %) vergleichbar. Etwa die Hälfte aller Patienten erhielt mindestens drei Chemotherapielinien, wobei im Zeitraum 1 vor allem eine alleinige Chemotherapie (> 80 %) und im Zeitraum 2 die Kombination einer Chemotherapie mit einem monoklonalen Antikörper (ca. 70 %) eingesetzt wurde. Zudem stieg die Rate der sekundären Metastasenchirurgie im Verlauf an (8 vs. 17 %). Das mediane Überleben lag im Zeitraum 1 bei 27,3 Monaten und im Zeitraum 2 bei 39,4 Monaten. In beiden Patientenkollektiven waren die Überlebenszeiten umso länger, je besser das Therapieansprechen in der Erstlinie ausfiel. Folgerung: Das zunehmende Gesamtüberleben bei Patienten mit mKRK ist möglicherweise durch die wachsende Anzahl an effektiven und zugelassenen Substanzen sowie den zunehmenden Einsatz von monoklonalen Antikörpern und sekundärer Metastasenchirurgie bedingt. Background and aim: In metastatic colorectal cancer (mCRC) available systemic treatment options substantially increased in the last decades. Nowadays, overall survival in mCRC patients ranges from 25 to 35 months as recent studies report. We compared treatment modalities and survival in mCRC patients who were treated at our center in two different periods. Patients and methods: Within two sequential monocentric analyses patients with mCRC treated at our Comprehensive Cancer Center (CCC) between 07/1994 and 10/2007 (cohort 1) and from 11/2007 to 05/2010 (cohort 2) were evaluated for applied treatment, for best response to treatment and for survival (OS). For statistical analysis the Kaplan-Meier estimator was used. Results: Both patient cohorts showed comparable characteristics regarding median age (63 vs. 64 yrs), localization of primary tumor (colon 60 % vs. rectum 40 %) and number and site of distant metastasis (1 site [75 %] vs. ≥ 2 site [25 %]; liver-only metastasis [55 %]). About half of all patients in each cohort received at least three consecutive chemotherapy regimens. In cohort 1, treatment mainly consisted of chemotherapy alone (> 80 %), whereas in cohort 2 chemotherapy was combined with a monoclonal antibody in nearly 70 %. Rate of surgical resection of metastasis increased over time (8 % vs. 17 %). Median OS was 27.3 months (cohort 1) vs. 39.4 months (cohort 2). Conclusion: The increasing availability of effective substances including monoclonal antibodies and individual approaches including secondary surgery of distant metastasis might explain that survival in pts with mCRC has substantially improved over the last decades.


  • Open Access

    Second consensus on medical treatment of metastatic breast cancer

    by S. Beslija, J. Bonneterre, H. Burstein, V. Cocquyt, M. Gnant, P. Goodwin, V. Heinemann, J. Jassem, W.J. Köstler, M. Krainer, et al.

    The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on disease-associated and biologic variables.


  • Hepatic artery infusion of 5-fluorouracil, folinic acid plus oxaliplatin for liver metastasis from colorectal cancer. Final analysis of a phase I/II studay

    by N. Moosmann, W. Kern, T. Waggershauser, W. Hiddemann, V. Heinemann, A. Schalhorn

    3628 Objective: Numerous studies and meta-analyses have shown significantly higher response rates of hepatic artery infusion (HAI) compared to systemic chemotherapy for liver metastasis from colorectal cancer (CRC). The combination of oxaliplatin with 5-FU and folinic acid can be safely administered as HAI. This final analysis of a phase I-/II-study evaluates toxicity and efficacy of this intraarterial regimen. Methods: Patients with histologically documented CRC with exclusive liver metastasis after surgery of the primary tumor were included. Pts received HAI with folinic acid (200mg/m2, 1 hour infusion) followed by 5-FU (600mg/m2, 2 hour infusion) on days 1 to 5, combined with oxaliplatin (62,5mg/m2, 4 hour infusion) on days 2 and 4. As a long term intrahepatic access, a chamber device was implanted into the groin connected to a catheter radiologically placed into the hepatic artery. Supportive treatment consisted of a 5-HT3-receptor antagonist p.o., paracetamol 1000mg p.o. and a H2-antagonist. Furthermore dexamethasone 8mg p.o. was given 30 min prior and 2 hours after application of oxaliplatin. Results: Twenty-four pts were enrolled (66% colon cancer, 34% rectum cancer). Median age was 62 years (range 34–77), ECOG PS≤2. They were either chemonaive (n=14) or had received an adjuvant treatment ≥6 months before start of study (n=10). Median number of HAI cycles was 7 (range 2–26). WHO grade 3/4-toxicities included leucopenia (19%), thrombocytopenia (10%), hyperbilirubinemia (10%), diarrhea (5%), and abdominal pain (10%). The overall response rate was 70,8%. Complete remission was observed in 5 pts (20,8%), PR in 12 pts (50%), 3 pts obtained SD (12,5%), and 4 had PD (16,7%). Median TTP was 8,8 months. Median overall survival reached 25,5 months. Four years after start of treatment, 5 pts (20,8%) were alive. Two pts (8,3%) had obtained partial liver resection, and 2 pts (8,3%) were treated with radiofrequency ablation after remission had been achieved by the intrahepatic chemotherapy. Conclusion: This final analysis indicates that HAI of 5-FU, folinic acid and oxaliplatin is safe and highly effective in patients with exclusive liver metastasis from CRC. No significant financial relationships to disclose.


  • Phase III trial of irinotecan plus oxaliplatin (IROX) versus irinotecan plus 5-FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): The FIRE-Trial

    by A. Schalhorn, F. W. Ludwig, D. Quietzsch, P. A. Maubach, G. Schlimok, H. Lambertz, K. Weigang-Koehler, M. Schulze, R. Schlag, M. Grundeis, et al.

    3516 Objective: This randomised cross-over study compares the 1st-line efficacy and toxicity of infusional 5-FU/FA (AIO regimen) plus irinotecan (FOLFIRI) to the combination of irinotecan plus oxaliplatin (IROX). Methods: 488 patients (pts) from 56 centres were enrolled between July 2000 and the end of study in September 2004. In the FOLFIRI arm, pts received FA 500mg/m2 plus 5-FU 2000 mg/m2 (24h) and irinotecan 80mg/m2 given weekly for 6 times. In the IROX arm pts were treated with oxaliplatin 85mg/m2 (d1, 15, 29) and irinotecan 80mg/m2 weekly times 6. Treatment cycles were repeated on day 50 in both treatment arms. Patients were stratified according to LDH, adjuvant pretreatment, and Karnofsky performance status (KPS) showing LDH >240 U/ml in 42% vs 39%, adjuvant pretreatment in 31% vs 29%, and a KPS=100% in 48% vs 47%, in the FOLFIRI- and IROX-arm respectively. The primary end-point of the trial was progression-free survival. At disease progression, pts were offered to switch to the comparator regimen. Results: At the time of analysis, treatment efficacy was evaluable in 299 pts (157 FOLFIRI, 142 IROX). The complete remission rate (CR) was 8% in both arms, the partial remission rate (PR) 38% vs 42% for an overall remission rate (CR+PR) of 46% vs 50%. Stable disease (SD) was documented in 47% vs 33% resulting in a disease control rate (CR+PR+SD) of 92% vs 83%. In the FOLFIRI- and the IROX-arm respectively, median progression-free survival was 8.7 months (95% CI, 7.3–9,6) vs 7.3 months (95% CI, 6.4–8.2) (p=0.15), while median overall survival was 21.1 months (95% CI, 18.8–27.2) vs 18.6 months (95% CI, 16.3–22.8) (p=0.23). Treatment was stopped due to toxicity in 8.5% vs 16.5%, and 60-day mortality was 5.5% and 3.4% (FOLFIRI vs IROX). Conclusions: FOLFIRI and IROX are comparably effective with regard to response, progression-free survival, and overall survival. Toxicity is similarly acceptable in both treatment arms.


  • Gemcitabine in metastatic breast cancer

    by Volker Heinemann

    Gemcitabine is a pyrimidine antimetabolite which has shown activity in metastatic breast cancer both as a single agent, but also in various combination regimens. It is characterized by a unique mechanism of action which includes cytotoxic self-potentiation, masked DNA chain termination and potent inhibition of DNA repair. The clinical application of gemcitabine is supported by a favorable toxicity profile. In metastatic breast cancer, several Phase II trials document the activity of gemcitabine in pretreated and unpretreated patients. In a single Phase III trial performed in elderly patients not pretreated, gemcitabine was inferior to epirubicin. High activity has, however, been obtained by the combination of gemcitabine with taxanes such as paclitaxel or docetaxel. In a randomized trial performed in anthracycline-pretreated patients, the combined use of gemcitabine and paclitaxel induced a significant improvement not only of response rate and time to disease progression, but also caused a significant increase in quality of life and survival when compared with paclitaxel alone. The combination of gemcitabine with vinorelbine and cisplatin has been validated in numerous Phase II trials and promises reliable activity in anthracycline- and/or taxane-pretreated patients. Triple-agent regimens such as gemcitabine/epirubicin/paclitaxel provided consistently high response rates in Phase II trials, but failed to show superiority over the 5-fluorouracil/epirubicin/cyclophosphamide regimen in a randomized Phase III trial. Based on high response rates and pathological complete remission rates achieved by preoperative induction therapy with gemcitabine/epirubicin/taxane regimens, ongoing trials focus on the incorporation of gemcitabine into neoadjuvant and adjuvant regimens.


  • Role of Gemcitabine in the Treatment of Advanced and Metastatic Breast Cancer

    by Volker Heinemann

    Gemcitabine is an antimetabolite drug with proven antitumor activity and tolerability in metastatic breast cancer. In a total of nine studies, gemcitabine monotherapy has reached response rates of up to 37% in the first-line setting, 26% in the second-line setting, and 18% or better in the third-line setting. Gemcitabine is an excellent choice for combination therapy by its unique mechanism of action and favorable toxicity profile, thus limiting the risk of pretreatment-related drug resistance and overlapping toxicity, and by its potential for synergistic interaction with some combination partners as indicated in preclinical studies. Numerous phase II clinical studies have combined gemcitabine with other active agents such as the taxanes, vinorelbine, vindesine, cisplatin, 5-fluorouracil, as well as anthracyclines across various regimens and conditions of pretreatment. Most of these two-drug combinations have consistently demonstrated higher efficacy than either single agent, particularly in pretreated patients. Even higher efficacy has been obtained with triple-drug regimens including gemcitabine, anthracyclines (epirubicin or doxorubicin), and paclitaxel; these regimens have yielded overall response rates of 58–92% as first-line treatment. In view of these results, gemcitabine may be regarded as a valuable alternative to the palliative treatment of metastatic breast cancer, and an excellent option for the development of effective combination treatment not only in first-line therapy, but also for intensively pretreated patients previously exposed to anthracyclines and/or the taxanes.


  • Gemcitabine: Progress in the Treatment of Pancreatic Cancer

    by Volker Heinemann

    Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3–5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor. Treatment with single-agent gemcitabine achieved clinical benefit and symptoms improvement in 20–30% of patients. While 1-year survival was observed in 2% of 5-fluorouracil (5-FU)-treated patients, it was raised to 18% by single-agent gemcitabine. Good treatment tolerability and low incidence of side effects are clear advantages of single-agent gemcitabine. Improvement of efficacy is, however, expected from combination treatment. Gemcitabine and cisplatin given as first-line treatment in three studies achieved a median survival of 7.4–8.3 months. One-year survival was raised to 28% as reported in one study. Comparable activity was obtained by a combination of gemcitabine with 5-FU. Nine studies using gemcitabine in combination with standard-dose or high-dose 5-FU reported a median survival ranging from 5.5 to 13 months. Notwithstanding these promising results, recommendations regarding palliative chemotherapy of pancreatic cancer remain tentative and still need confirmation by presently ongoing phase III trials. Inclusion of pancreatic cancer patients into clinical trials should be a major goal. Outside clinical trials, patients should present with an adequate PS (Karnofsky-performance index ≧70) to qualify for chemotherapy.


  • Open Access

    Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer

    by V. Heinemann, H. Wilke, H.-G. Mergenthaler, M. Clemens, H. König, H. J. Illiger, M. Arning, A. Schalhorn, K. Possinger, U. Fink